A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

Purpose: This is the first study to compare the pharmacokinetics, safety and, immunogenicity of QL1209, a biosimilar of Perjeta®.Methods: This study was a randomized, double-blind, parallel-controlled clinical trial evaluating the biosimilarity between QL1209 (specification: 420 mg:14 ml, single use...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Yuanyuan Sun, Heng Yang, Xiaoyan Yang, Shuang Yang, Can Guo, Honghui Chen, Chang Cui, Yuxia Xiang, Guoping Yang, Jie Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Subjects:	QL1209 pertuzumab biosimilar pharmacokinetics safety immunogenicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.953641/full